Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Gastroenterology
Published in: BMC Gastroenterology 1/2012

Open Access 01-12-2012 | Research article

Prevalence and factors associated with nonalcoholic fatty liver disease in shanghai work-units

Authors: Xiaona Hu, Yiqin Huang, Zhijun Bao, Yiqian Wang, Dongmei Shi, Fang Liu, Zhanjuan Gao, Xiaofeng Yu

Published in: BMC Gastroenterology | Issue 1/2012

Login to get access

Abstract

Backgrounds

Nonalcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease in Asians. However, data on prevalence and factors associated with NAFLD in Asians are lacking. The aim of this study is to investigate the prevalence of NAFLD in Shanghai employees to assess the relationship between NAFLD and age, gender, metabolic risk factors in this studied population.

Methods

We selected 7152 employees of Shanghai work-units. Each of them underwent detailed medical history-taking, physical examination, laboratory assessments and abdominal ultrasonography. The diagnosis of NAFLD was done according to established criteria. Receiver operating characteristics (ROC) curves were applied to detect areas under the ROC curves for each index. Nominal logistic regression analysis was used to estimate the odds ratio for risk factors of NAFLD.

Results

About 38.17% employees had NAFLD, more in men than in women. The prevalence of NAFLD increased with increasing age. In both genders, the prevalence of metabolic factors was higher in the NAFLD group. Body max index, waist circumference, weight-to-height ratio, blood pressure, blood glucose, total cholesterol, triglyceride, low density lipoprotein, high density lipoprotein and uric acid were found to have a diagnostic value for NAFLD. Body max index is a better index for diagnosing NAFLD. Uric acid is a new diagnosing index not inferior to lipid metabolic factors. Metabolic factors can increase the risk of NAFLD up to 1.5 ~ 3.8 times.

Conclusions

Older age, male gender, metabolic factors such as obesity, abdominal obesity, dyslipidemia, hypertension or type 2 diabetes are risk factors for NAFLD. Prevalence of NAFLD in Shanghai employees is high. Prevention is extremely important. Those achieve the critical point should have early intervention.
Appendix
Available only for authorised users
Literature
1.
Amarapurkar DN, Hashimoto E, Lesmana LA, Sollano JD, Chen PJ, Goh KL: How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences?. J Gastroenterol Hepatol. 2007, 22 (6): 788-793. 10.1111/j.1440-1746.2007.05042.x.CrossRefPubMed
2.
Fan JG, Saibara T, Chitturi S, Kim BI, Sung JJ, Chutaputti A: What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific?. J Gastroenterol Hepatol. 2007, 22 (6): 794-800. 10.1111/j.1440-1746.2007.04952.x.CrossRefPubMed
3.
Caballeria L, Auladell MA, Toran P, Miranda D, Aznar J, Pera G, Gil D, Munoz L, Planas J, Canut S, et al: Prevalence and factors associated with the presence of non alcoholic fatty liver disease in an apparently healthy adult population in primary care units. BMC Gastroenterol. 2007, 7: 41-10.1186/1471-230X-7-41.CrossRefPubMedPubMedCentral
4.
Bellentani S, Scaglioni F, Marino M, Bedogni G: Epidemiology of non-alcoholic fatty liver disease. Dig Dis. 2010, 28 (1): 155-161. 10.1159/000282080.CrossRefPubMed
5.
Kojima S, Watanabe N, Numata M, Ogawa T, Matsuzaki S: Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J Gastroenterol. 2003, 38 (10): 954-961. 10.1007/s00535-003-1178-8.CrossRefPubMed
6.
Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, Omatsu T, Nakajima T, Sarui H, Shimazaki M, et al: The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005, 143 (10): 722-728.CrossRefPubMed
7.
Guturu P, Duchini A: Etiopathogenesis of Nonalcoholic Steatohepatitis: Role of Obesity. Insulin Resistance and Mechanisms of Hepatotoxicity. Int J Hepatol. 2012, 2012: 212865-CrossRefPubMedPubMedCentral
8.
Gan L, Chitturi S, Farrell GC: Mechanisms and implications of age-related changes in the liver: nonalcoholic Fatty liver disease in the elderly. Curr Gerontol Geriatr Res. 2011, 2011: 831536-PubMedPubMedCentral
9.
Hamaguchi M, Kojima T, Ohbora A, Takeda N, Fukui M, Kato T: Aging is a risk factor of nonalcoholic fatty liver disease in premenopausal women. World J Gastroenterol. 2012, 18 (3): 237-243. 10.3748/wjg.v18.i3.237.CrossRefPubMedPubMedCentral
10.
Hernaez R: Genetic factors associated with the presence and progression of nonalcoholic fatty liver disease: a narrative review. Gastroenterol Hepatol. 2012, 35 (1): 32-41. 10.1016/j.gastrohep.2011.08.002.CrossRefPubMed
11.
12.
Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL, Harrison SA: Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011, 140 (1): 124-131. 10.1053/j.gastro.2010.09.038.CrossRefPubMed
13.
Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH: Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004, 40 (6): 1387-1395. 10.1002/hep.20466.CrossRefPubMed
14.
Pasumarthy L, Srour J: Nonalcoholic steatohepatitis: a review of the literature and updates in management. South Med J. 2010, 103 (6): 547-550. 10.1097/SMJ.0b013e3181de0ce0.CrossRefPubMed
15.
Hashimoto E, Tokushige K: Prevalence, gender, ethnic variations, and prognosis of NASH. J Gastroenterol. 2011, 46 (Suppl 1): 63-69.CrossRefPubMed
16.
Scatarige JC, Scott WW, Donovan PJ, Siegelman SS, Sanders RC: Fatty infiltration of the liver: ultrasonographic and computed tomographic correlation. J Ultrasound Med. 1984, 3 (1): 9-14.PubMed
17.
Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, Mullen KD, Cooper JN, Sheridan MJ: The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002, 123 (3): 745-750. 10.1053/gast.2002.35354.CrossRefPubMed
18.
Quinn SF, Gosink BB: Characteristic sonographic signs of hepatic fatty infiltration. AJR Am J Roentgenol. 1985, 145 (4): 753-755.CrossRefPubMed
19.
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JJ, Jones DW, Materson BJ, Oparil S, Wright JJ, et al: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003, 289 (19): 2560-2572. 10.1001/jama.289.19.2560.CrossRefPubMed
20.
Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003, 26 (Suppl 1): S5-S20.
21.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001, 285 (19): 2486-2497. 10.1001/jama.285.19.2486.CrossRef
22.
Tan CE, Ma S, Wai D, Chew SK, Tai ES: Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians?. Diabetes Care. 2004, 27 (5): 1182-1186. 10.2337/diacare.27.5.1182.CrossRefPubMed
23.
Farrell GC, Chitturi S, Lau GK, Sollano JD: Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary. J Gastroenterol Hepatol. 2007, 22 (6): 775-777. 10.1111/j.1440-1746.2007.05002.x.CrossRefPubMed
24.
Fan JG, Jia JD, Li YM, Wang BY, Lu LG, Shi JP, Chan LY: Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: update 2010: (published in Chinese on Chinese Journal of Hepatology 2010; 18:163–166). J Dig Dis. 2011, 12 (1): 38-44. 10.1111/j.1751-2980.2010.00476.x.CrossRefPubMed
25.
Vernon G, Baranova A, Younossi ZM: Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011, 34 (3): 274-285. 10.1111/j.1365-2036.2011.04724.x.CrossRefPubMed
26.
Fan JG, Farrell GC: Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol. 2009, 50 (1): 204-210. 10.1016/j.jhep.2008.10.010.CrossRefPubMed
27.
Li H, Wang YJ, Tan K, Zeng L, Liu L, Liu FJ, Zhou TY, Chen EQ, Tang H: Prevalence and risk factors of fatty liver disease in Chengdu, Southwest China. Hepatobiliary Pancreat Dis Int. 2009, 8 (4): 377-382.PubMed
28.
Fan JG, Zhu J, Li XJ, Chen L, Li L, Dai F, Li F, Chen SY: Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol. 2005, 43 (3): 508-514. 10.1016/j.jhep.2005.02.042.CrossRefPubMed
29.
Zhou YJ, Li YY, Nie YQ, Ma JX, Lu LG, Shi SL, Chen MH, Hu PJ: Prevalence of fatty liver disease and its risk factors in the population of South China. World J Gastroenterol. 2007, 13 (47): 6419-6424. 10.3748/wjg.13.6419.CrossRefPubMedPubMedCentral
30.
Lee K, Sung JA, Kim JS, Park TJ: The roles of obesity and gender on the relationship between metabolic risk factors and non-alcoholic fatty liver disease in Koreans. Diabetes Metab Res Rev. 2009, 25 (2): 150-155. 10.1002/dmrr.924.CrossRefPubMed
31.
Ruhl CE, Everhart JE: Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology. 2003, 124 (1): 71-79. 10.1053/gast.2003.50004.CrossRefPubMed
32.
Omagari K, Kadokawa Y, Masuda J, Egawa I, Sawa T, Hazama H, Ohba K, Isomoto H, Mizuta Y, Hayashida K, et al: Fatty liver in non-alcoholic non-overweight Japanese adults: incidence and clinical characteristics. J Gastroenterol Hepatol. 2002, 17 (10): 1098-1105. 10.1046/j.1440-1746.2002.02846.x.CrossRefPubMed
33.
Singh SP, Nayak S, Swain M, Rout N, Mallik RN, Agrawal O, Meher C, Rao M: Prevalence of nonalcoholic fatty liver disease in coastal eastern India: a preliminary ultrasonographic survey. Trop Gastroenterol. 2004, 25 (2): 76-79.PubMed
34.
Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, Boerwinkle E, Cohen JC, Hobbs HH: Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008, 40 (12): 1461-1465. 10.1038/ng.257.CrossRefPubMedPubMedCentral
35.
Daly AK, Ballestri S, Carulli L, Loria P, Day CP: Genetic determinants of susceptibility and severity in nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol. 2011, 5 (2): 253-263. 10.1586/egh.11.18.CrossRefPubMed
36.
Anstee QM, Daly AK, Day CP: Genetics of alcoholic and nonalcoholic fatty liver disease. Semin Liver Dis. 2011, 31 (2): 128-146. 10.1055/s-0031-1276643.CrossRefPubMed
37.
Angulo P: GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2007, 25 (8): 883-889. 10.1111/j.1365-2036.2007.03246.x.CrossRefPubMed
38.
Ryu S, Chang Y, Kim SG, Cho J, Guallar E: Serum uric acid levels predict incident nonalcoholic fatty liver disease in healthy Korean men. Metabolism. 2011, 60 (6): 860-866. 10.1016/j.metabol.2010.08.005.CrossRefPubMed
39.
Xu C, Yu C, Xu L, Miao M, Li Y: High serum uric acid increases the risk for nonalcoholic Fatty liver disease: a prospective observational study. PLoS One. 2010, 5 (7): e11578-10.1371/journal.pone.0011578.CrossRefPubMedPubMedCentral
40.
Lee JW, Cho YK, Ryan M, Kim H, Lee SW, Chang E, Joo KJ, Kim JT, Kim BS, Sung KC: Serum uric Acid as a predictor for the development of nonalcoholic Fatty liver disease in apparently healthy subjects: a 5-year retrospective cohort study. Gut Liver. 2010, 4 (3): 378-383. 10.5009/gnl.2010.4.3.378.CrossRefPubMedPubMedCentral
41.
Li Y, Xu C, Yu C, Xu L, Miao M: Association of serum uric acid level with non-alcoholic fatty liver disease: a cross-sectional study. J Hepatol. 2009, 50 (5): 1029-1034. 10.1016/j.jhep.2008.11.021.CrossRefPubMed
42.
Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S: Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology. 2005, 42 (1): 44-52. 10.1002/hep.20734.CrossRefPubMed
43.
Metadata
Title
Prevalence and factors associated with nonalcoholic fatty liver disease in shanghai work-units
Authors
Xiaona Hu
Yiqin Huang
Zhijun Bao
Yiqian Wang
Dongmei Shi
Fang Liu
Zhanjuan Gao
Xiaofeng Yu
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2012
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/1471-230X-12-123

Other articles of this Issue 1/2012

BMC Gastroenterology 1/2012 Go to the issue

Research article

Role of vitamin K2 in preventing the recurrence of hepatocellular carcinoma after curative treatment: A meta-analysis of randomized controlled trials

Research article

Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic review

Study protocol

The value of pancreatic stone protein in predicting acute appendicitis in patients presenting at the emergency department with abdominal pain

Research article

Increased proton pump inhibitor and NSAID exposure in irritable bowel syndrome: results from a case-control study

Research article

Resolvin D1 reverses chronic pancreatitis-induced mechanical allodynia, phosphorylation of NMDA receptors, and cytokines expression in the thoracic spinal dorsal horn

Research article

Nasogastric tube insertion in anesthetized and intubated patients: a new and reliable method
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits